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Transplanta b s t r a c t
There are limited data on the outcomes of autologous or allogeneic hematopoietic cell transplantation (HCT) in
diffuse large B cell lymphoma transformed from follicular lymphoma.We analyzed transplantation outcomes in
141 subjectswith biopsy-proven diffuse largeB-cell lymphoma transformed from follicular lymphoma reported
to the Center for International Blood and Marrow Transplant Research between 1990 and 2009. Two groups
were identiﬁed: autologous HCT (auto-HCT; n ¼ 108) and allogeneic HCT (allo-HCT; n ¼ 33). Fewer auto-HCTs
were done for transformed follicular lymphoma in 2003 to 2009, with a shift favoring allo-HCT. Auto-HCT was
associated with a 1-year nonrelapse mortality (NRM) of 8% (95% conﬁdence interval [CI], 4% to 14%), 5-year
progression-free survival of 35% (95% CI, 26% to 45%), and 5-year overall survival of 50% (95% CI, 40% to 59%).
In contrast, allo-HCT was associated with a 1-year NRM of 41% (95% CI, 23% to 58%), 5-year progression-free
survival of 18% (95% CI, 6% to 35%), and 5-year overall survival of 22% (95% CI, 8% to 41%). Auto-HCT for trans-
formed follicular lymphoma achieves sustained remission in a high proportion of subjects. The high NRM of
allo-HCT offset any beneﬁt that might be associated with this transplantation modality.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION transformation to DLBCL were included in this study. All pathology reports
Follicular lymphoma (FL) is the second most common
form of non-Hodgkin lymphoma (NHL) in the Western
Hemisphere [1,2]. The histological transformation of FL to
diffuse large B-cell lymphoma (DLBCL) occurs in up to 30% of
patients at 10 years [3-7]. The rate of such transformed FL
(tFL) varies according to the deﬁnition of transformation used
(ie, whether the deﬁnition includes onlyDLBCL or also Burkitt
lymphoma, grade 3B FL, and composite or discordant lym-
phomas), method of diagnosis (biopsy, cytology, or clinical
suspicion), duration of follow-up, and inclusion of autopsy
data [8].
Compared with FL, in which the median survival is his-
torically in the 10-year rangewithout a plateau, tFL is usually
associated with chemotherapy resistance and shorter sur-
vival after chemotherapy [9-13]. There is no standard of care
for tFL; therapy for tFL is based mainly on guidelines for de
novo advanced DLBCL. Because patients with tFL are typically
excluded from FL and DLBCL clinical trials, data on the role of
autologous (auto-) or allogeneic (allo-) hematopoietic cell
transplantation (HCT) in tFL are limited. Most of the reports
published to date are small retrospective studies with brief
follow-up [14-20]. Outcomes vary greatly owing to the
differing inclusion criteria [14-20]. In addition, most of the
studies were conducted before the availability of rituximab,
an agent that has improved the outcomes of patients with FL
and DLBCL [14-20]. In the present study, we analyzed the
outcomes of auto-HCT and allo-HCT for biopsy-proven
transformation of FL to DLBCL in a larger patient cohort re-
ported to the Center for International Blood and Marrow
Transplant Research (CIBMTR).
METHODS
Data Source
The CIBMTR comprises a voluntary network of more than 500 trans-
plantation centers globally that submit comprehensive data on consecutive
autotransplants and allotransplants to a centralized statistical center. The
CIBMTR is a combined research program of theMedical College ofWisconsin
and the National Marrow Donor Program. Protected health information
during the performance of this observational research is collected and
maintained in the CIBMTR’s capacity as a Public Health Authority under the
Health Insurance Portability and Accountability Act (HIPAA). The observa-
tional research is conducted with a waiver of informed consent and in
compliance with all applicable federal regulations regarding the protection
of human research participants as assessed by the Institutional Review
Board and the Privacy Ofﬁcer at the Medical College of Wisconsin. Further
information on the data source has been provided by Horowitz [21].
Patient Population
Patients age 18 years with FL at diagnosis by the World Health Orga-
nization classiﬁcation [22] with subsequent biopsy-proven histologicalfrom the centers were reviewed at the CIBMTR to conﬁrm transformation to
DLBCL. Histological transformation to DLBCLwas deﬁned as large centroblasts
diffusely inﬁltrating the lymph nodes and effacing the follicular architecture.
Cases of composite or discordant lymphoma at diagnosis were not included.
Patients with histological transformation of other low-grade lymphomas,
such as marginal zone lymphoma and chronic lymphocytic leukemia, were
excluded, as were those with transformation to histology other than DLBCL,
such as Burkitt lymphoma, lymphoblastic lymphoma, and Hodgkin lym-
phoma. Patientswhohadundergone an initial single auto-HCTor allo-HCT for
tFL were included, whereas those who had undergone a previous HCT for FL
before transformation or after transformation were excluded.
Study Endpoints and Deﬁnitions
The main objective of this study was to describe the outcomes of auto-
HCT and allo-HCT for patients with DLBCL transformed from FL. The primary
endpoint was overall survival (OS), and other endpoints of interest were
progression-free survival (PFS), relapse/progression, nonrelapse mortality
(NRM), and the incidence of acute graft-versus-host disease (aGVHD) and
chronic GVHD (cGVHD). OS was deﬁned as time to death after trans-
plantation. Death from any cause was considered an event, and surviving
patients were censored at the time of last follow-up. PFS was deﬁned as
survival without disease relapse or progression after transplantation.
Relapse or progression of disease and death were events. Relapse/progres-
sion was deﬁned as any new lesion after complete remission or increase in
size of previously involved sites after transplantation, with NRM as a
competing risk [23]. NRM was deﬁned as any death within the ﬁrst 28 days
after transplantation or any death occurring after day 28 in the absence of
disease relapse/progression. Relapse was a competing risk. Those who sur-
vived without relapse or progression were censored at last contact for PFS,
relapse/progression, and NRM. aGVHDwas diagnosed by established criteria
[24], as was cGVHD [25]. The intensity of the conditioning regimen was
deﬁned based on CIBMTR criteria [26]. Related donor and unrelated donor
(URD) transplant recipients were classiﬁed based on available HLA typing, as
described by Weisdorf et al. [27].
Statistical Methods
Univariate probabilities of OS and PFS for the auto-HCT and allo-HCT
cohorts were calculated using the Kaplan-Meier estimator, with the vari-
ance estimated using the formula of Greenwood [28]. Variables considered
for univariate analysis were age, Karnofsky Performance Status, presence of
extranodal disease at transplantation, previous use of rituximab, chemo-
resistance, interval from diagnosis of FL to transformation, and total body
irradiation (TBI)-based conditioning. For allo-HCT, additional variables
tested were use of reduced-intensity conditioning (RIC)/nonmyeloablative
conditioning (NMAC), antithymocyte globulin (ATG), alemtuzumab, and
donor source. Relapse/progression, NRM, and the incidence of aGVHD and
cGVHD were estimated using cumulative incidence estimates to accom-
modate for competing risk.
A Cox proportional hazards regression model was used to identify the
risk factors signiﬁcantly associated with treatment failure (1 e PFS) and
overall mortality (1 e OS) for auto-HCT. A multivariate analysis was not
considered for allo-HCT, owing to the small size of the study cohort. The
variables considered in the multivariate models are listed in Table 2. The
assumption of proportional hazards for each factor in the Cox model was
tested by adding a time-dependent covariate. The proportionality assump-
tion was satisﬁed for each factor. A forward and backward stepwise model
selection approach was used to identify all signiﬁcant risk factors.
Table 1
Characteristics of Patients with Transformed DLBCL from FL Who Under-
went HCT between 1990 and 2009
Variable Auto-HCT Allo-HCT
Number of patients 108 33
Age, yr, median (range) 56 (19-74) 49 (31-66)
Sex, n (%)
Male 65 (60) 20 (61)
Female 43 (40) 13 (39)
Karnofsky Performance Scale, n (%)
<90% 35 (32) 8 (24)
90%-100% 68 (63) 25 (76)
Missing 5 (5) 0
Stage at diagnosis, n (%)
I-II 32 (30) 9 (27)
III-IV 72 (67) 23 (70)
Missing 4 (4) 1 (3)
Disease status before HCT, n (%)
CR1 9 (8) 2 (6)
CR2 23 (21) 7 (21)
Primary induction failure sensitive 13 (12) 7 (21)
Primary induction failure resistant 3 (3) 3 (10)
Relapsed sensitive 39 (36) 7 (21)
Relapsed resistant 5 (5) 5 (15)
Relapse untreated 5 (5) 1 (3)
Missing* 11 (10) 1 (3)
Chemosensitivity before HCT, n (%)
Sensitive 90 (83) 23 (70)
Resistant 10 (10) 8 (24)
Untreated/unknown 8 (7) 2 (6)
Lines of chemotherapy before HCT, n (%)
1-2 33 (31) 7 (21)
3 66 (61) 26 (79)
Missing 9 (8) 0
Rituximab exposure between diagnosis
and HCT, n (%)
No 78 (72) 11 (33)
Yes 30 (28) 22 (67)
Known extranodal disease immediately
before HCT, n (%)
No 75 (69) 24 (73)
Yes 28 (26) 9 (27)
Missing 5 (5) 0
Size of involved lymph nodes at HCT, n (%)
<5 cm 18 (17) 4 (12)
5 cm 14 (13) 2 (6)
No lymphadenopathy at HCT 35 (32) 19 (58)
Missing 41 (38) 8 (24)
Interval between diagnosis and HCT,
mo, median (range)
54 (6-347) 55 (8-203)
Interval between diagnosis and
transformation, mo, median (range)
47 (1-281) 48 (1-173)
Interval between HCT and transformation,
mo, median (range)
6 (2-76) 8 (1-31)
Conditioning regimen, n (%)
Myeloablative 108 (100) 20 (61)
Reduced-intensity 11 (33)
Missing 2 (6)
TBI-based conditioning, n (%)
No 84 (78) 20 (61)
Yes 24 (22) 12 (36)
Missing 0 1 (3)
Graft type, n (%)
Bone marrow 16 (15) 10 (30)
Peripheral blood 92 (85) 23 (70)
Use of ATG/alemtuzumab, n (%)
ATG/alemtuzumab 0 10 (30)
No ATG/alemtuzumab 0 23 (70)
Autologous 108 (100) 0
Type of donor, n (%)
Matched related donor 0 15 (45)
Matched unrelated donor 0 9 (27)
Other 0 9 (27)
Autologous 108 (100) 0
(Continued)
Table 1
(continued)
Variable Auto-HCT Allo-HCT
Year of HCT, n (%)
1990-1994 32 (30) 1 (3)
1995-2002 51 (47) 9 (27)
2003-2009 25 (23) 23 (70)
Follow-up of survivors, mo, median (range) 85 (3-233) 64 (3-97)
* Chemosensitivity known for 8 cases.
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Subject, Disease, and Transplantation-Related Variables
Two groups reported to the CIBMTR between 1990 and
2009 were identiﬁed: 108 subjects who underwent auto-HCT
and33whounderwent allo-HCTwithout a previous auto-HCT
(Table 1). Median follow-up in the 2 groups was 85 months
and 64 months, respectively. Overall completeness index of
the follow-up for the population at 5 years was 89% [29]. The
majority of the auto-HCTs were performed between 1990 and
2002, whereas most allo-HCTs were done between 2003 and
2009. The median interval from diagnosis of FL to tFL was 47
months in the auto-HCTgroup and 48months in the allo-HCT
group. Disease variables at the time of diagnosis of tFL were
unavailable. The median interval from diagnosis of FL to
transplantationwas similar in the 2 groups (54months versus
55 months), as was the interval from the diagnosis of tFL to
transplantation (6 months versus 8 months).
Rituximab was given pretransplantation in 28% of the
auto-HCT group and in 61% of the allo-HCT group (Table 1).
Radioimmunotherapy with 90Y-ibritumomab tiuxetan or
131I-tositumomab was given to 5 subjects (1 auto-HCT recip-
ient [0.9%] and 4 allo-HCT recipients [12%]). The majority of
subjects were responsive to chemotherapy before trans-
plantation in both the auto-HCTgroup (83%) and the allo-HCT
group (70%). However, patients with poor risk features at
transplantation were also included in this study. The rate of
chemoresistance at transplantation was 10% in the auto-HCT
group and 24% in the allo-HCT group. The median number of
previous lines of chemotherapy was 3 in the auto-HCT group
and 4 in the allo-HCT group, indicating a heavily pretreated
cohort. Furthermore, bulky lymphadenopathy of 5 cm was
present at transplantation in 13% of the auto-HCT recipients
and 6% of the allo-HCT recipients, and extranodal disease was
present at transplantation in 26% of the auto-HCT group and
27% of the allo-HCT group, indicating a sizeable fraction of
patients with poor risk features at transplantation. Cytoge-
netic data were not available.
In the auto-HCT group, conditioning was provided with a
combination of carmustine, etoposide, cytarabine,melphalan
(BEAM) in 27% of patients and with cyclophosphamide,
carmustine, etoposide (CBV) in 29%. Most allo-HCT recipients
(61%) received myeloablative conditioning (MAC) with cy-
clophosphamide and total body irradiation (Cy/TBI). The
remaining subjects reeived RIC/NMAC, primarily with ﬂu-
darabine and 2 Gy of TBI, ﬂudarabine and cyclophosphamide,
or ﬂudarabine and melphalan.
Transplantation Outcomes
The auto-HCT group had a 1 year NRM of 8% (95% conﬁ-
dence interval [CI], 4% to 14%), 5-year probability of relapse/
progression of 54% (95% CI, 44% to 63%), 5-year PFS of 35%
(95% CI, 26% to 45%), and 5-year OS of 50% (95% CI, 40% to
Table 2
Univariate Survival Analysis for Auto-HCT
Covariate n Treatment Failure (1 - PFS) Overall Mortality (1 - OS)
HR (95% CI) P Value HR (95% CI) P Value
TBI-based conditioning
No 84 Reference Reference
Yes 24 1.27 (0.75-2.14) .38 1.41 (0.82-2.44) .22
Chemosensitivity .38* .32*
Sensitive 90 Reference Reference
Resistant 10 1.89 (0.90-3.97) .09 1.98 (0.89-4.40) .09
Time from diagnosis to transformation
<1 yr 17 Reference Reference
1 yr 91 0.69 (0.37-1.29) .25 0.68 (0.35-1.31) .25
Age
>60 yr 39 Reference Reference
60 yr 69 1.06 (0.66-1.72) .80 1.20 (0.71-2.02) .50
Karnofsky Performance Status .50* .71*
<90% 35 Reference Reference
90%-100% 68 0.76 (0.46-1.24) .27 0.81 (0.48-1.37) .43
Extranodal disease before HCT .25* .66*
No 75 Reference Reference
Yes 28 0.95 (0.56-1.60) .85 0.84 (0.48-1.49) .55
Rituximab exposure before HCT
No 78 Reference Reference
Yes 30 0.99 (0.59-1.67) .98 0.65 (0.35-1.20) .17
* Multiple degree-of-freedom overall test.
B. Wirk et al. / Biol Blood Marrow Transplant 20 (2014) 951e95995459%). The group had a 40-month plateau at 39% (95% CI, 30%
to 48%) for PFS and 53% (95% CI, 43% to 63%) for OS (Figure 1).
Causes of death included relapse/progression (41%) and
second cancers (4%).
The allo-HCT group had a 1-year NRM of 41% (95% CI,
23% to 58%), 5-year probability of relapse/progression of
33% (95% CI, 17% to 50%), 5-year PFS of 18% (95% CI, 6% to
35%), and 5-year OS of 22% (95% CI, 8% to 41%). The cu-
mulative incidences of grade II-IV and grade III-IV aGVHD
at day 100 was 42% (95% CI, 26% to 59%) and 27% (95% CI,
14% to 42%), respectively. The cumulative incidence ofFigure 1. Kaplan-Meier curves focGVHD at 1 year was 26% (95% CI, 13% to 43%). The major
causes of death were organ failure (24%), relapse/pro-
gression (18%), and GVHD (12%). For MAC allo-HCT re-
cipients, the 3-year PFS was 11% (95% CI, 1% to 30%) and
3-year OS was 11% (95% CI, 1% to 29%). For NMAC/RIC
allo-HCT recipients, the 3-year PFS was 48% (95% CI, 18% to
79%) and 3-year OS was 67% (95% CI, 35% to 93%). The
1-year NRM for MAC allo-HCT was 57% (95% CI, 31% to
77%). RIC/NMAC allo-HCT recipients did not experience
NRM within 5 years, but 5 of the 13 patients (38%) died of
relapse/progression.r PFS and OS for auto-HCT.
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For the auto-HCT group, age, Karnofsky Performance Sta-
tus, presence of extranodal disease at HCT, pretransplantation
rituximab use, time interval from diagnosis of FL to tFL of 1
year versus <1 year, chemosensitivity, and TBI conditioning
did not have a statistically signiﬁcant impact on PFS or OS
(Table 2). Of note, auto-HCT recipients with chemotherapy-
resistant disease achieved a 3 year OS of 27% (95% CI, 7% to
59%) after transplantation.
For the allo-HCT group, age, Karnofsky Performance Sta-
tus, presence of extranodal disease at HCT, pretransplantation
rituximab use, time interval from diagnosis of FL to tFL of 1
year versus <1 year, chemosensitivity, use of ATG or alem-
tuzumab, and donor source did not have a statistically
signiﬁcant impact on PFS or OS (Table 3). Subjects with
chemotherapy-resistant disease achieved a 3 year OS of 21%
(95% CI, 0 to 62%) after allo-HCT. The 3-year PFS was 11% (95%
CI, 1% to 30%) for MAC allo-HCT recipients and 48% (95% CI,
18% to 79%) for RIC/NMAC allo-HCT recipients (P ¼ .001), and
the 3-year OS was 11% (95% CI, 1% to 29%) for MAC allo-HCT
recipients and 67% (95% CI, 35% to 93%) for RIC/NMAC allo-
HCT recipients (P <.001). RIC/NMAC was associated with
signiﬁcantly higher PFS and OS compared with MAC (Table 3
and Figure 2).Multivariate Analysis
A Cox proportional hazards regression model was used to
identify risk factors signiﬁcantly associated with treatment
failure (1 e PFS) and overall mortality (1 e OS) in the auto-
HCT. At a 5% signiﬁcance level, no risk factors wereTable 3
Univariate Survival Analysis for Allo-HCT
Covariate n PFS
HR (95% CI)
TBI-based conditioning
No 20 Reference
Yes 12 1.07 (0.46-2.
Chemosensitivity
Sensitive 23 Reference
Resistant 8 1.36 (0.52-3.
Time from diagnosis to transformation
<1 yr 9 Reference
1 yr 24 0.43 (0.18-1.
Age
>50 yr 15 Reference
50 yr 18 0.66 (0.29-1.
Karnofsky Performance Status
<90% 8 Reference
90%-100% 25 0.88 (0.34-2.
Extranodal disease before HCT
No 24 Reference
Yes 9 2.21 (0.91-5.
Rituximab exposure before HCT
No 11 Reference
Yes 22 1.28 (0.52-3.
ATG/alemtuzumab use
ATG and/or alemtuzumab 10 Reference
No ATG and/or alemtuzumab 23 1.51 (0.59-3.
Conditioning regimen intensity
Myeloablative 20 Reference
RIC/NMAC 11 0.16 (0.04-0.
Disease status at HCT
Complete remission 8 Reference
Primary induction failure/relapse 21 1.07 (0.38-2.
Donor type
HLA-identical sibling 12 Reference
Unrelated donor 18 0.95 (0.39-2.
* Multiple degree-of-freedom overall test.signiﬁcant. Multivariate analysis was not considered for allo-
HCT, owing to the small size of the study cohort.DISCUSSION
Our ﬁndings indicate that auto-HCT for tFL results in
durable remissions in a high proportion of recipients. There
was an unexpectedly high NRM in the allo-HCT recipients
that might have offset any beneﬁt seen with allo-HCT. It is
interesting that clinicians seemingly favored the use of allo-
HCT in the 2003 to 2009 period. Given this study’s retro-
spective nature, we cannot discern why clinicians chose
auto-HCT or allo-HCT. The pretransplantation variables were
comparable in the auto-HCT and allo-HCT groups in terms of
risk factors and markers of poor prognosis. Availability of a
good donor is not the explanation, given that more than one-
half of the patients in both groups did not have a matched
sibling. Perhaps the choice reﬂects a perception that auto-
HCT is less effective at producing long-term remission for
tFL in the rituximab era. There are limited data on the impact
of previous rituximab on outcomes of auto-HCT for tFL
[16,30]. We found a 5-year PFS of 35% (95% CI, 26% to 45%)
and a 5-year OS of 50% (95% CI, 40% to 59%) after auto-HCT for
tFL, with a seemingly similar beneﬁt in those who had pre-
vious rituximab therapy. Only 28% of patients received rit-
uximab before auto-HCT, however, and thus ﬁrm conclusions
regarding the impact of previous rituximab therapy await
larger studies. The plateau seen for PFS and OS suggests that
a subset of patients may be cured with auto-HCT, although
longer follow-up is needed to determine whether these pa-
tients remain disease-free.OS
P Value HR (95% CI) P Value
Reference
49) .88 0.93 (0.40-2.18) .87
Reference
52) .53 1.30 (0.50-3.37) .59
Reference
03) .06 0.53 (0.23-1.25) .15
Reference
50) .32 0.64 (0.28-1.45) .28
Reference
24) .79 0.80 (0.31-2.05) .64
Reference
37) .08 2.06 (0.86-4.96) .11
Reference
11) .59 1.40 (0.57-3.40) .46
Reference
84) .39 1.66 (0.65-4.23) .29
.01* .007*
Reference
54) .004 0.14 (0.04-0.49) .002
.24* .31*
Reference
98) .90 0.90 (0.32-2.52) .84
.53* .29*
Reference
32) .92 0.82 (0.34-2.01) .67
Figure 2. Kaplan-Meier curves for (A) PFS and (B) OS for allo-HCT by conditioning regimen intensity.
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Marrow Transplant registry report of 50 subjects with tFL
fromthepre-rituximab era (Table 4) [17]. The sole prospective
phase 2 study of patients with tFL, also pre-rituximab, re-
ported a 5-year OS of 47% (95% CI, 29% to 65%) with auto-HCT,
which compares favorably with values in transplantation-
ineligible patients [31]. More recently, the Canadian Blood
and Marrow Transplant Group reported a 5-year OS of 61%
(standard error, 7%)with rituximab containing chemotherapy
alone without transplantation; however, one-third of thissubset of patients had received no therapy for FL before his-
tological transformation, and one-quarter had limited-stage
tFL, a highly favorable subset that likely contributed to these
results [32]. Even in the pre-rituximab era, watchful waiting
before transformation and limited stage of tFL were signiﬁ-
cant predictors of long-term survival (median survival, 81
months), albeit with a continuous risk of relapse and without
aplateauon the survival curve [3,5,33]. In contrast,we founda
plateau on the survival curve with auto-HCT in our heavily
pretreated cohort. A key limitation to analyses such as ours is
Table 4
Studies on Outcomes of Auto-HCT for tFL
Authors/Type of Study/Years of HCT n Patient Age, yr,
Median (Range)
TL Deﬁnition PFS OS NRM Comments
Pre-rituximab era
Williams et al. [17]/EBMT retrospective/1982-1995 50 auto-HCT 45 (28-61) FL/ DLBCL or any high-grade
lymphoma
2 yr, 40%
5 yr, 30%
2 yr, 60%
5 yr, 51%
18% Improved survival if chemosensitive at HCT. Same outcomes
for FL, de novo relapsed DLBCL, and transformed lymphoma
in matched controlled analysis.
Friedberg et al. [18]/retrospective/1982-1997 27 auto-HCT 44 (29-58) FL/ DLBCL; CLL/ DLBCL 5 yr, 46% 5 yr, 58% 0 All relapses after auto-HCT were DLBCL. tFL within 18 mo
of diagnosis had better OS.
Eide et al. [31]/prospective, phase 2/1991-2007 30 auto-HCT 55 (31-65) FL or MZL/ DLBCL or between DLBCL
and BL, composite lymphoma
5 yr, 32% 5 yr, 47% 7% Plateau on PFS after 40 mo at 30%.
Rituximab era
Hamadani et al. [16]/retrospective/1991-2007 24 auto-HCT 56 (47-68) FL/ DLBCL 3 yr, 40% 3 yr, 52% 8% Improved PFS in 62% of patients with rituximab in treatment
course.
Chemosensitivity at HCT had no effect on outcomes after HCT.
Ban-Hoefen et al. [30]/retrospective/1998-2010 18 auto-HCT 58 (40-65) FL or MZL/ DLBCL 2 yr, 59% 2 yr, 82% 0 Improved outcomes compared with historical pre-rituximab
cohorts [17].
Villa et al. [32]/CBMTG retrospective/2001-2010 97 auto-HCT 56 (32-66) FL/ DLBCL or BL 5 yr, 55% 5 yr, 57% 5% Auto-HCT had better PFS/OS than rituximab-chemotherapy.
Present study/retrospective/1990-2009 108 auto-HCT 56 (19-74) FL/ DLBCL 5 yr, 36% 5 yr, 50% 8% No impact of chemosensitivity or previous rituximab use on
outcomes.
BL indicates Burkitt lymphoma; MZL, marginal zone lymphoma; EBMT, European Bone Marrow Transplant Registry; CBMTG, Canadian Blood and Marrow Transplant Group; CLL, chronic lymphocytic leukemia; TL, transfomed
lymphoma.
Table 5
Studies on Outcomes of Allo-HCT for tFL
Study/n of Patients/Years
of HCT
Age, yr, Median
(Range)
TL Deﬁnition Median Lines of
Chemotherapy before HCT
Conditioning/
Donor
PFS OS NRM Comments
Ramadan et al. [19]/
n ¼ 40/1989- 2005
44 (28-57) FL, SLL, MZL/ intermediate- or
higher-grade lymphoma;
composite lymphoma
3; chemoresistance, 20% MAC
MRD, 25
URD, 15
5 yr, 23% 5 yr, 23% 3 yr, 36% No impact on outcomes of composite versus
transformed lymphomas or of URD versus MRD.
Performance of HCT within 1 yr of diagnosis
associated with better outcomes.
Rezvani et al. [20]/n ¼ 62;
16 with TL/1998-2006
54 (33-66) FL, SLL, MZL/ aggressive NHL
in 16 patients; remainder
had low-grade lymphoma
6; chemoresistance, 23% NMAC, 2 Gy
TBI  ﬂudarabine
MRD, 34
URD, 28
3 yr, 21% for TL
3 yr, 43% for FL
3 yr, 18% for TL
3 yr, 52% for FL
3 yr, 42% Better outcomes for indolent lymphomas
versus transformed lymphoma; no impact
of chemoresistance at HCT. 27 patients had
previous auto-HCT.
Hamadani et al. [35]/
n ¼ 8/1999-2007
56 (44-63) FL/ DLBCL 4; chemoresistance, 38% MAC, 6
RIC, 2
MRD, 5
URD, 3
4 yr, 56% 4 yr, 66% 25% No disease relapse after 1 yr.
Villa et al. [32]/CBMTG/
n ¼ 22/2001-2010
48 (32-57) FL/ DLBCL, BL 3; chemoresistance, 18% MAC, >95%
MRD, 14
URD, 7
MMRD, 1
5 yr, 45% 5 yr, 45% 5 yr, 23% Two patients had previous auto-HCT for FL. No
difference in OS between recipients of allo-HCT
and recipients of auto-HCT.
Present study/
n ¼ 33/1990-2009
49 (31-66) FL/ DLBCL 4; chemoresistance, 35% MAC, 20
RIC/NMAC, 5/6
MRD, 12
URD, 21
5 yr, 18% 5 yr, 22% 1 yr, 41%
5 yr, 49%
No impact of chemoresistance at HCT or URD on
outcomes. Better 3-yr PFS/OS with RIC/NMAC
compared with MAC (48%/67% versus 11%).
MRD indicates matched related donor; MMRD, mismatched related donor; SLL, small lymphocytic lymphoma; URD, unrelated donor; TL, transformed lymphoma.
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that auto-HCT is a better approach than nontransplantation
therapies. However, the durability of the response is an
important advantage of auto-HCT for tFL. Likewise, in the
largest study of radioimmunotherapy for tFL, the response
rates were high, but durability was poor, with a 5-year PFS of
only 17% [34].
In the present study, RIC/NMAC allo-HCT was associated
with better PFS and OS comparedwithMAC allo-HCT (Table 3
and Figure 2). The high NRM after MAC allo-HCT inﬂuenced
these outcomes and so cannot be recommended. RIC/NMAC
allo-HCT may be the best strategy for solving the problem of
NRM in allo-HCT, because the low NRM with RIC/NMAC did
not obscure the potential beneﬁts of allo-HCT. Firm conclu-
sions about the role of RIC/NMAC allo-HCT in tFL await pro-
spective comparisons with auto-HCT. Nonetheless, outcomes
of allo-HCT for tFL appear to be inferior to those of FL. In the
study of Khoury et al. [36], NMAC allo-HCT for FL was asso-
ciated with a 5-year OS of 85% (95% CI, 71% to 93%) with a
plateau on the survival curve, implying a curative potential
and stronger graft-versus-lymphoma effect. In a recent
CIBMTR analysis, GVHD was associated with lower relapse in
FL, but not in de novo DLBCL, and this effect was more
prominent with RIC than with MAC [37]. Similar to de novo
DLBCL, graft-versus-lymphoma effects seem to be less effec-
tive in transformed DLBCL than in FL [38].
This study has the limitations of any retrospective study,
including inherent patient selection bias as to the type of
transplantation performed. The comparison of auto-HCT and
allo-HCT is biased, given thatmost auto-HCTswere performed
a decade before the allo-HCTs. Furthermore, the number of
allo-HCT recipients is low, and RIC/NMACwas associatedwith
signiﬁcantly better results compared with MAC, hindering a
direct comparison of allo-HCT and auto-HCT. Nonetheless, to
the best of our knowledge, thismulticenter study is the largest
to date that describes transplantation outcomes speciﬁcally in
biopsy-proven DLBCL transformed from FL. Some previous
studies have included heterogeneous low-grade lymphomas
transforming to various high-grade lymphomas, all of which
can inﬂuence transplantation outcomes and make the results
difﬁcult to interpret (Tables 4 and 5) [17-20,30-32].
Several conclusions can be drawn from our results. First,
RIC/NMAC allo-HCT was associated with better survival
compared with MAC allo-HCT, but any potential beneﬁt from
MAC was offset by the high NRM. The precise role of allo-HCT
awaits prospective comparison of RIC/NMAC allo-HCT and
auto-HCT. Second, auto-HCT provides durable survival for tFL
irrespective of age, early or late histological transformation,
extranodal disease at transplantation, or previous rituximab
use. The outcomes of auto-HCT seem to be more durable than
published data on nontransplantation therapies, meriting a
prospective study to deﬁnitively answer this question [7,31-
34].
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